Tel:
+49 (0)241 95 163 153
Fax:
+49 (0)241 95 163 155
E-Mail:
orders@anticorps-enligne.fr

CDKN3 anticorps (N-Term)

L’anticorps Lapin Polyclonal anti-CDKN3 a été validé pour WB. Il convient pour détecter CDKN3 dans des échantillons de Humain. Il y a 5+ publications disponibles.
N° du produit ABIN1881194

Aperçu rapide pour CDKN3 anticorps (N-Term) (ABIN1881194)

Antigène

Voir toutes CDKN3 Anticorps
CDKN3 (Cyclin-Dependent Kinase Inhibitor 3 (CDKN3))

Reactivité

  • 67
  • 23
  • 13
  • 4
  • 4
  • 3
  • 3
  • 2
  • 2
  • 2
Humain

Hôte

  • 61
  • 6
Lapin

Clonalité

  • 63
  • 4
Polyclonal

Conjugué

  • 27
  • 6
  • 6
  • 5
  • 3
  • 3
  • 1
  • 1
  • 1
  • 1
  • 1
  • 1
  • 1
  • 1
  • 1
  • 1
  • 1
  • 1
  • 1
  • 1
  • 1
  • 1
  • 1
Cet anticorp CDKN3 est non-conjugé

Application

  • 54
  • 31
  • 16
  • 13
  • 13
  • 7
  • 6
  • 4
  • 3
  • 3
  • 3
  • 1
Western Blotting (WB)

Clone

RB42328
  • Épitope

    • 15
    • 8
    • 8
    • 6
    • 6
    • 3
    • 2
    • 2
    • 1
    • 1
    • 1
    • 1
    • 1
    • 1
    AA 39-68, N-Term

    Purification

    This antibody is purified through a protein A column, followed by peptide affinity purification.

    Immunogène

    This CDKN3 antibody is generated from rabbits immunized with a KLH conjugated synthetic peptide between 39-68 amino acids from the N-terminal region of human CDKN3.

    Isotype

    Ig Fraction
  • Indications d'application

    WB: 1:1000

    Restrictions

    For Research Use only
  • Format

    Liquid

    Buffer

    Purified polyclonal antibody supplied in PBS with 0.09 % (W/V) sodium azide.

    Agent conservateur

    Sodium azide

    Précaution d'utilisation

    This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.

    Stock

    4 °C,-20 °C

    Date de péremption

    6 months
  • Jiang, Xia, Li, Deng, Zhao, Shi, Wang, Sun: "High expression levels of IKKalpha and IKKbeta are necessary for the malignant properties of liver cancer." dans: International journal of cancer. Journal international du cancer, Vol. 126, Issue 5, pp. 1263-74, (2010) (PubMed).

    Shimada, Miyagawa, Kawashima, Tanaka, Honda, Honda, Tokunaga: "An approach based on a genome-wide association study reveals candidate loci for narcolepsy." dans: Human genetics, Vol. 128, Issue 4, pp. 433-41, (2010) (PubMed).

    Okamoto, Kitabayashi, Taya: "KAP1 dictates p53 response induced by chemotherapeutic agents via Mdm2 interaction." dans: Biochemical and biophysical research communications, Vol. 351, Issue 1, pp. 216-22, (2006) (PubMed).

    Hsieh, Yao, Lai, Yang: "Transcriptional repression activity of PAX3 is modulated by competition between corepressor KAP1 and heterochromatin protein 1." dans: Biochemical and biophysical research communications, Vol. 349, Issue 2, pp. 573-81, (2006) (PubMed).

    Chinami, Yano, Yang, Salahuddin, Moriyama, Shiroishi, Turner, Shirakawa, Adra et al.: "Binding of HTm4 to cyclin-dependent kinase (Cdk)-associated phosphatase (KAP).Cdk2.cyclin A complex enhances the phosphatase activity of KAP, dissociates cyclin A, and facilitates KAP..." dans: The Journal of biological chemistry, Vol. 280, Issue 17, pp. 17235-42, (2005) (PubMed).

  • Antigène

    CDKN3 (Cyclin-Dependent Kinase Inhibitor 3 (CDKN3))

    Autre désignation

    CDKN3

    Sujet

    The protein encoded by this gene belongs to the dual specificity protein phosphatase family. It was identified as a cyclin-dependent kinase inhibitor, and has been shown to interact with, and dephosphorylate CDK2 kinase, thus prevent the activation of CDK2 kinase. This gene was reported to be deleted, mutated, or overexpressed in several kinds of cancers. Alternatively spliced transcript variants encoding different isoforms have been found for this gene.

    Poids moléculaire

    23805

    NCBI Accession

    NP_001124323, NP_005183

    UniProt

    Q16667
Vous êtes ici:
Chat with us!